Curium Pharma   Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: Paris France (2017)
Status: Defunct (2015)

Organization Overview

First Clinical Trial
2022
NCT05204927
First Marketed Drug
2017
sodium iodide i-131 (iodotope)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

CURIUM | Curium US LLC